Recent Advances in Parkinson´s Disease Research, Volume 252, represents a follow-up on two previous volumes presented in the Progress in Brain Research series, Volumes 193 and 193, both published in 2010. It contains a collection of overview articles written by leading researchers in Parkinson's, discussing the most important advances made in basic, translational and clinical research. Topics of note in this new release include What can we learn from iPS cell models of PD, What can we learn from animal models of PD?, Molecular basis of selective neuronal vulnerability in PD, Role of innate and adaptive immunity in Parkinson´s disease, and much more.
- Covers all key aspects of current research on Parkinson´s disease
- Includes topics that range from basic studies on disease models and pathogenic pathways (e.g., protein misfolding, immune and glial mechanisms) to clinical studies on disease features, microbiome, pathophysiology and therapeutic approaches
- Presents articles authored by world leaders in their respective fields
an update Tiago Fleming Outeiro 5. New vistas on the role of glial cells in neurodegeneration and regeneration Katarzyna Z. Kuter 6. Role of innate and adaptive immunity in Parkinson´s disease David George Standaert 7. Pathways of protein synthesis and degradation in the pathogenesis of PD Mark R. Cookson 8. Pathways of endosomal sorting and trafficking in the pathogenesis of PD Darren Moore 9. Circuit breakdown: new players in basal ganglia dysfunctions in PD Elena Moro 10. Prodromal PD: a new nosological entity and therapy indication Kirsten E. Zeuner 11. The gut microbiome in PD: a culprit or a bystander? Roberto Cilia 12. New approaches to gene therapy in PD Vania Broccoli 13. New approaches to counter protein aggregation pathology Patrik Brundin 14. Repurposing antidiabetic drugs for the treatment of PD: rationale and clinical experience Tom Foltynie 15. Basal ganglia oscillations as biomarkers for targeting circuit dysfunctions in PD Per Petersson 16. Pharmacological targets for symptomatic and disease-modifying therapies
an update Per Svenningsson